Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial DNA topoisomerase IV (TopoIV) is an essential type II DNA topoisomerase in bacteria. It is a heterotetrameric enzyme composed of ParC and ParE subunits, forming an A2B2 complex. TopoIV primarily functions in decatenating interlinked daughter chromosomes after DNA replication and relaxing positive supercoils. It is a validated antibacterial drug target, inhibited by quinolones like ciprofloxacin, leading to bacterial cell death due to chromosome segregation failure.
Inhibition of DNA breakage and rejoining, leading to chromosome segregation failure.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial DNA topoisomerase IV (TopoIV).